Phase I and pilot study of subcutaneous homoharringtonine [omacetaxine mepesuccinate] in chronic myelogenous leukemia (CML).

Trial Profile

Phase I and pilot study of subcutaneous homoharringtonine [omacetaxine mepesuccinate] in chronic myelogenous leukemia (CML).

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Omacetaxine mepesuccinate (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov.
    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top